Comparative remission rates of schizophrenic patients using various remission criteria
Authors:
- Stefan LeuchtSLStefan Leucht
- 1 October 2008
- journal article
- Published by Elsevier in Progress in Neuro-Psychopharmacology and Biological Psychiatry
- Vol. 32 (7) , 1643-1651
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Symptomatic remission in schizophrenia patients treated with aripiprazole or haloperidol for up to 52 weeksSchizophrenia Research, 2007
- The relationship between symptomatic remission and neuropsychological improvement in schizophrenia patients switched to treatment with ziprasidoneSchizophrenia Research, 2007
- Remission in prognosis of functional outcome: A new dimension in the treatment of patients with psychotic disordersSchizophrenia Research, 2007
- Remission criteria for schizophrenia: Evaluation in a large naturalistic cohortSchizophrenia Research, 2007
- Remission in early psychosis: Rates, predictors, and clinical and functional outcome correlatesSchizophrenia Research, 2007
- Remission and cognitive ability in a cohort of patients with schizophreniaJournal of Psychiatric Research, 2006
- Olanzapine Versus Ziprasidone: Results of a 28-Week Double-Blind Study in Patients With SchizophreniaAmerican Journal of Psychiatry, 2005
- Remission in Schizophrenia: Proposed Criteria and Rationale for ConsensusAmerican Journal of Psychiatry, 2005
- Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trialEuropean Neuropsychopharmacology, 1997
- Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trialPsychopharmacology, 1996